Screener
Halozyme Therapeutics HALO Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Total current liabilities | 344,439 | 177,092 |
| Long-term debt, net | 1,937,684 | 2,142,630 |
| Other long-term liabilities | 102,681 | 113,863 |
| Deferred tax liabilities, net | 49,061 | 42,924 |
| Total liabilities | 2,433,865 | 2,476,509 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity | ||
| Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding | — | — |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's deferred tax assets?
- Halozyme Therapeutics (HALO) reported deferred tax assets of $49.06M in Q2 2026.
- How has Halozyme Therapeutics's deferred tax assets changed year-over-year?
- Halozyme Therapeutics's deferred tax assets increased by 142.8% year-over-year, from $20.21M to $49.06M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.
Ask your AI about Halozyme Therapeutics's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude